Bioprinted heart-on-a-chip for drug evaluation
2022
Universidad de Extremadura, Badajoz, Spain
The aim of this study was to develop a user-friendly bioprinting setup that minimally affects the physiology of human pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). At each stage, the new method was compared with the traditional approach (manual pipetting) to ensure the reliability of the results. First, the electrophysiological behaviour of hiPSC-CMs plated using the bioprinting technique and common hydrogels and their precursor solutions was compared with traditionally manually plated cells using a common matrix (fibronectin). To demonstrate the suitability of the bioprinting technique for drug assay evaluation, hiPSC-CMs were plated using the bioprinter or the traditional method (manual pipetting) and treated with three previously well-characterized drugs (E4031, flecainide, and nifedipine). The electrophysiology of these cells was assessed using the CellOPTIQ® high-throughput optical platform. The response of bioimprinted or manually plated cells to E4031, nifedipine and flecainide was as expected in both cases, providing further evidence of the usefulness of the CellOPTIQ® system. The results thus provide the basis for a bioprinting-based strategy using bioprinting and substrate modification methods to replace traditional manual culture methods for high-throughput drug evaluation.
A bioprinted heart-on-a-chip with human pluripotent stem cell-derived cardiomyocytes for drug evaluation
Maria P. Hortigon-Vinagre
Added on: 04-14-2022
[1] https://www.mdpi.com/2306-5354/9/1/32
